Shanghai Jizhi Biochemical Technology Co., Ltd
China
Product Name: Razoxane
Price: ￥1526.0/100mg ￥6086.0/1g ￥2436.0/250mg
Purity: 95.0%
Stocking Period: 2 Day
Contact: Liu jia

DC Chemicals Limited
China
Product Name: Razoxane
Price: $Inquiry/100mg $Inquiry/250mg $Inquiry/500mg
Purity: 98.0%
Stocking Period: 3 Day
Contact: Tony Cao

Dayang Chem (Hangzhou) Co., Ltd.
China
Product Name: 4,4'-Propylene-bis(piperazine-2,6-dione)
Price: $Inquiry/100g $Inquiry/1kg $Inquiry/100kg $Inquiry/1000kg
Purity: 98.0%
Stocking Period: Inquiry
Contact: Ms Wang

21416-67-1

21416-67-1 structure

21416-67-1 structure

Name: Razoxane
Chemical Name: 4,4'-(Propane-1,2-diyl)bis(piperazine-2,6-dione)
CAS Number: 21416-67-1
Molecular Formula: C₁₁H₁₆N₄O₄
Molecular Weight: 268.26900
Catalog: Biochemical Inhibitor Immune inhibitor
Create Date: 2018-06-20 18:11:28
Modify Date: 2024-01-07 14:47:17
Razoxane (ICRF 159) is an antiangiogenic topoisomerase II inhibitor, can be used for the research of renal cell carcinoma (RCC)[1].

Name	4,4'-(Propane-1,2-diyl)bis(piperazine-2,6-dione)
Synonyms	4,4'-propylenebis(piperazine-2,6-dione) 4,4'-Propane-1,2-diyldipiperazine-2,6-dione 4,4'-(1-Methylethylene)bis(2,6-piperazinedione) dl-1,2-bis(3,5-dioxopiperazin-1-yl)-propane Propyliminum RAZOXANUM 1,2-bis(3,5-dioxopiperazin-1-yl)-propane (+)-1,2-bis(3,5-dioxopiperazinyl)propane (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane Razoxane

Description	Razoxane (ICRF 159) is an antiangiogenic topoisomerase II inhibitor, can be used for the research of renal cell carcinoma (RCC)[1].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Cell Cycle/DNA Damage >> Topoisomerase
Target	Topoisomerase II
In Vitro	Razoxane (30 mg/kg; i.p.) exhibits antimetastatic effects in a rat osteosarcoma model.
In Vivo	Early treatment with Razoxane (30 mg/kg i.p. from day -2 to +14) shows a greater inhibition of pulmonary metastases than later treatment (30 mg/kg i.p. from day +14 to +28 after transplantation)[2]. Animal Model: Sprague-Dawley rats[2] Dosage: 30 mg/kg or 10 mg/kg per day Administration: Intraperitoneally (i.p.) from 2 days before to 14 days after tumor transplantation Result: Resulted in a dose-dependent prolongation of median survival time (83 or 48 days respectively, versus 38 days for the control group), but showed no influence on the growth of the primary tumor.
References	[1]. J P Braybrooke, et al. A phase II study of Razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis. Clin Cancer Res.2000; 6(12):4697-704. [2]. F Wingen, et al. Antimetastatic effects of Razoxane in a rat osteosarcoma model. Clin Exp Metastasis.Jan-Mar 1987; 5(1):9-16.

Density	1.333g/cm3
Boiling Point	531.5ºC at 760mmHg
Melting Point	193ºC
Molecular Formula	C₁₁H₁₆N₄O₄
Molecular Weight	268.26900
Flash Point	275.3ºC
Exact Mass	268.11700
PSA	98.82000
Vapour Pressure	1.33E-13mmHg at 25°C
Index of Refraction	1.534
Storage condition	room temp
Water Solubility	DMSO: soluble40mg/mL

CHEMICAL IDENTIFICATION

RTECS NUMBER :: TL6389900

CHEMICAL NAME :: 2,6-Piperazinedione, 4,4'-propylenedi-

CAS REGISTRY NUMBER :: 21416-67-1

BEILSTEIN REFERENCE NO. :: 0821182

LAST UPDATED :: 199612

DATA ITEMS CITED :: 15

MOLECULAR FORMULA :: C11-H16-N4-O4

MOLECULAR WEIGHT :: 268.31

WISWESSER LINE NOTATION :: T6VMV ENTJ EY1&1- ET6VMV ENTJ

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 3650 mg/kg/2Y-I

TOXIC EFFECTS :: Kidney, Ureter, Bladder - hematuria Blood - aplastic anemia

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Unreported

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 600 mg/kg/34W-I

TOXIC EFFECTS :: Blood - leukopenia

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Unreported

SPECIES OBSERVED :: Human - man

DOSE/DURATION :: 6467 mg/kg/6Y-I

TOXIC EFFECTS :: Blood - normocytic anemia Blood - thrombocytopenia

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 500 mg/kg

TOXIC EFFECTS :: Tumorigenic - active as anti-cancer agent

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - man

DOSE/DURATION :: 693 mg/kg/77W-I

TOXIC EFFECTS :: Tumorigenic - Carcinogenic by RTECS criteria Blood - leukemia

TYPE OF TEST :: TD - Toxic dose (other than lowest)

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 4650 mg/kg/2Y-C

TOXIC EFFECTS :: Tumorigenic - Carcinogenic by RTECS criteria Blood - leukemia

TYPE OF TEST :: TD - Toxic dose (other than lowest)

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - man

DOSE/DURATION :: 2693 mg/kg/3Y-C

TOXIC EFFECTS :: Tumorigenic - Carcinogenic by RTECS criteria Skin and Appendages - tumors

TYPE OF TEST :: TD - Toxic dose (other than lowest)

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 3650 mg/kg/2Y-I

TOXIC EFFECTS :: Tumorigenic - Carcinogenic by RTECS criteria Blood - leukemia

TYPE OF TEST :: Micronucleus test

MUTATION DATA

TEST SYSTEM :: Rodent - hamster

DOSE/DURATION :: 100 mg/kg

REFERENCE :: BJCAAI British Journal of Cancer. (Macmillan Press Ltd., Houndmills, Basingstoke, Hants. RG21 2XS, UK) V.1- 1947- Volume(issue)/page/year: 52,725,1985

RIDADR	NONH for all modes of transport
RTECS	TL6389900